糖皮质激素性骨质疏松症骨代谢与糖皮质激素用药时间的相关性
Relevance between bone metabolism of glucocorticoid-induced osteoporosis and duration of glucocorticoid treatment

DOI: 10.6040/j.issn.1671-7554.0.2016.1681

Keywords: 糖皮质激素性骨质疏松症,系统性红斑狼疮,糖皮质激素,骨代谢标志物,骨密度,
Glucocorticoid-induced osteoporosis,Systemic lupus erythematosus Glucocorticoid,Bone metabolism,Bone mineral density

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Shusuke U, Toru I. Osteocytic cell necrosis is caused by a combination of glucocorticoid-induced Dickkopf-1 and hypoxia[J]. Med Mol Morphol, 2015, 48(2): 69-75.
[2]	Rizzoli R, Adachi JD, Cooper C, et al.Management of glucocorticoid-induced Osteoporosis[J].Calcif TIssue Int, 2012, 91(4):225-243.
[3]	Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced Osteoporosis[J].Arthritis Care Res, 2010, 62(11):1515-1526.
[4]	Kearns AE, Khosla S, Kostenuik PJ. Receptor activatior of nuclear factor kappaB ligand and oateoprotegerin regulation of bone remodeling in health and disease[J]. Endcor Rev, 2008, 29(2):155-192.
[5]	Gifre L, Mongegal A, Peris P, et al.Effect of glucocorticoid treatment on Wnt signalling antagonists(sclerostin and Dkk-1)and their relationship with bone turnover[J]. Bone, 2013, 57(1): 272-276.
[6]	Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone[J]. Ann NY Acad Sci, 2002, 6(966): 73-81.
[7]	Weinstein RS.Glucocorticoid-induced Osteoporosis and Osteonecrosis[J].Endocrine Metab Clin North Am, 2012, 41(3):595-611.
[8]	Zimlichman E, Rothschild J, Shoenfeld Y, et al. Good prognosis for hospitalized SLE patients with non-related disease[J]. Autoimmun Rev, 2014, 13(11): 1090-1093.
[9]	Weinstein RS. Clinical practice:Glucocorticoid-induced bone disease[J]. N Engl J Med, 2011, 36(5): 62-70.
[10]	刘海春,张剑锋,陈允震.骨质疏松大鼠股骨生物力学特性与骨胶原质量变化的相关研究[J].山东大学学报(医学版),2009, 47(5): 42-46. LIU Haichun, ZHANG Jianfeng, CHEN Yunzhen. Bone collagen and biomechanical propertyies in the femur of osteoporosis rats[J]. Journal of Shandong University(Health Sciences), 2009, 47(5): 42-46.
[11]	Den Uyl D, Bultink IE, Lems WF. Adwances in glucocorticoid-induced osteoporosis[J]. Curr Rheumatol Rep, 2011, 13(3): 233-240.
[12]	Seibel MJ, Cooper MS, Zhou H. glucocorticoid-induced osteoporosis: mechanisms,management, and future perspectives[J]. Lancet Diabetes Endocrinol, 2013, 1(1): 59-70.
[13]	Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis(HORIZON): a multicentre,double-blind, double-dummy, randomised controlled trial[J]. Lancet, 2009, 373(9671): 1253-1263.
[14]	Qiang YW, Chen Y, Stepens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma[J]. Blood, 2008, 112(1): 196-207.
[15]	Humphrey EL, Williams JH, Davie MW, et al. Effects of dissociated glucocorticoid on OPG and RANKL in osteoblastic cells[J]. Bone, 2006, 38(5): 652-661.
[16]	郭惠芳,高丽霞.2014年风湿免疫病学主要临床进展[J].临床荟萃, 2015, 30(2): 167-173.
[17]	Lekamwasam S, Adachi JD, Agnusdei D, et al.A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis[J].Osteoporos Int, 2012, 23(9):2257-2276.
[18]	Robert RC. Mechanisms of impaired growth: effect of steroids on bone and cartilage[J]. Horm Res, 2009, 72(1): 30-35.
[19]	Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis[J]. N Engl J Med. 2007, 357(20): 2028-2039.

Full-Text